A federal review board voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is non-mandatory. The FDA has given no signal on whether it will follow the advice. The move came after weeks of stakeholder sessions. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could shift how the agency handles a part of the wellness market that is moving at speed. Market observers are watching to see if the FDA follows through on the vote. A spokesperson for the agency offered no set date for a follow-up. Backers argue the change would open up access to products that users favor. Critics warn that looser rules could weaken safeguards across a fast-scaling market. The vote only opens the door to a change, and the last word rests with the federal agency.